Biotech Battered To 2-Month Lows As Celgene Crashes
The S&P Biotech Index is now down 9% from its early October highs, extending losses today thanks to the collapse in Celgene's share price after it lowered its outlook.
As Bloomberg reports, Celgene Corp. dropped 18 percent in early U.S. trading after lowering its long-term profit target.